Headline: A Breakthrough in Immunology: UC Santiago Developing Vaccine Against Human Metapneumovirus
Meta Description: UC Santiago’s Institute of Immunology and Immunotherapy is pioneering a vaccine against human Metapneumovirus (hMPV), a leading cause of severe respiratory infections in children and the elderly.
In a significant advancement in the fight against global respiratory diseases, scientists at the Institute of Immunology and Immunotherapy (IMII) of the Pontifical Catholic University of Chile (UC Santiago) have developed a vaccine for the human Metapneumovirus (hMPV). This breakthrough, already proving effective in preclinical models, could be a game-changer in preventing severe respiratory infections caused by this elusive pathogen.
The hMPV, identified in 2001, is a virus that targets the respiratory tract, affecting primarily young children, seniors, and immunocompromised individuals. It can lead to complications like pneumonia and airway obstruction, often requiring mechanical ventilation. Currently, there are no specific treatments or vaccines available for hMPV, posing a substantial burden on global healthcare systems.
The IMII team, led by Dr. Alexis Kalergis, discovered the molecular mechanism by which hMPV evades the immune response. This revelation allowed them to design a vaccine that effectively counters the virus by activating dendritic cells, which stimulate key immune cells called T lymphocytes.
"The vaccine has shown high levels of protection in preclinical studies," Dr. Kalergis stated, with promising results published in The Journal of Immunology. The next step is human clinical trials, a crucial milestone on the path to distributing this vaccine to the public.
The IMII team also developed novel antibodies to combat hMPV, further bolstering the arsenal against this evasive pathogen. This breakthrough builds on Dr. Kalergis’ earlier work leading the development of the world’s first vaccine against respiratory syncytial virus (RSV), another major respiratory pathogen.
Transmitted primarily through respiratory secretions, hMPV has an incubation period of five to six days and symptoms that include fever, cough, and breathing difficulties. Young children and the elderly are disproportionately affected, making this vaccine development a highly anticipated advancement in global public health.
Image caption: Scientists at the Institute of Immunology and Immunotherapy of UC Santiago are developing a vaccine against the human Metapneumovirus. (Credit: UC Santiago)
Alt text: Researchers working on human Metapneumovirus vaccine.
Related reading